Literature DB >> 24732313

Induction of dendritic cell maturation in the skin microenvironment by soluble factors derived from colon carcinoma.

Jelle J Lindenberg1, Rieneke van de Ven1, Dinja Oosterhoff1, Claudia C Sombroek2, Sinéad M Lougheed1, Anita G M Stam2, Hans J P M Koenen3, Alfons J M van den Eertwegh1, Rik J Scheper2, Tanja D de Gruijl1.   

Abstract

Autologous tumor cell-based vaccines provide a wide range of tumor antigens and personalized neo-epitopes based on individual tumors' unique antigenic mutanome signatures. However, tumor-derived factors may hamper in situ maturation of dendritic cells (DC) and thus interfere with the generation of effective anti-tumor immunity. As the skin is a preferred site for tumor vaccine delivery, we investigated the influence of primary colon carcinoma-derived soluble factors on the maturation state of migrating DC in a human skin explant model. Primary tumor-derived supernatants (TDSN) enhanced the phenotypic maturation state of skin-emigrated DC, resulting in an increased T-cell stimulatory ability in an allogeneic mixed leukocyte response. In case of monocyte-derived DC a similar TDSN-induced maturation induction was found to entirely depend on cyclooxygenase (COX)-regulated prostaglandins. In contrast, the increase in skin-emigrated DC maturation was completely prostaglandin-independent, as evidenced by the inability of the COX inhibitor indomethacin to abrogate this TDSN-induced effect. Although TDSN conditioning affected a drop in IL-12p70 release by the skin-emigrated DC and induced a predominant Th17/Th22 transcriptional profile in subsequently stimulated T-cells, Th cell subset differentiation, as assessed by intracellular cytokine expression upon polyclonal priming and re-stimulation, was not affected. Comparative analysis of phenotypic and transcriptional profiles suggests that the observed maturational effects in skin-derived DC may have been induced by tumor-derived GM-CSF. In conclusion, soluble factors derived from whole-cell colon tumor vaccines will not negatively impact DC migration and maturation in human skin, but rather induce DC maturation that will facilitate the priming of a poly-functional Th cell response.

Entities:  

Keywords:  COX; GM-CSF; colon cancer; dendritic cells; prostaglandin; skin

Mesh:

Substances:

Year:  2014        PMID: 24732313      PMCID: PMC5396241          DOI: 10.4161/hv.28548

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  46 in total

1.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.

Authors:  M L Albert; M Jegathesan; R B Darnell
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

2.  Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.

Authors:  B W Tillman; T D de Gruijl; S A Luykx-de Bakker; R J Scheper; H M Pinedo; T J Curiel; W R Gerritsen; D T Curiel
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

3.  A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance.

Authors:  Tanja D de Gruijl; Claudia C Sombroek; Sinéad M Lougheed; Dinja Oosterhoff; Jan Buter; Alfons J M van den Eertwegh; Rik J Scheper; Herbert M Pinedo
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.

Authors:  C Menetrier-Caux; M C Thomachot; L Alberti; G Montmain; J Y Blay
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer.

Authors:  Shinichi Miyagawa; Junpei Soeda; Satoshi Takagi; Shiroh Miwa; Eri Ichikawa; Terumasa Noike
Journal:  Hum Pathol       Date:  2004-11       Impact factor: 3.466

6.  Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.

Authors:  Vincent A de Weger; Annelies W Turksma; Quirinus J M Voorham; Zelda Euler; Herman Bril; Alfons J van den Eertwegh; Elisabeth Bloemena; Herbert M Pinedo; Jan B Vermorken; Harm van Tinteren; Gerrit A Meijer; Erik Hooijberg
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

7.  Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.

Authors:  A R Dadabayev; M H Sandel; A G Menon; H Morreau; C J M Melief; R Offringa; S H van der Burg; C Janssen-van Rhijn; N G Ensink; R A E M Tollenaar; C J H van de Velde; P J K Kuppen
Journal:  Cancer Immunol Immunother       Date:  2004-06-17       Impact factor: 6.968

8.  IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin.

Authors:  M Cumberbatch; M Bhushan; R J Dearman; I Kimber; C E M Griffiths
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

9.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

10.  IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

Authors:  Jelle J Lindenberg; Dinja Oosterhoff; Claudia C Sombroek; Sinéad M Lougheed; Erik Hooijberg; Anita G M Stam; Saskia J A M Santegoets; Henk J Tijssen; Jan Buter; Herbert M Pinedo; Alfons J M van den Eertwegh; Rik J Scheper; Hans J P M Koenen; Rieneke van de Ven; Tanja D de Gruijl
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

View more
  2 in total

1.  Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.

Authors:  R van de Ven; H de Haan; M López González; J van Eck van der Sluijs; W Dong; V W van Beusechem; T D de Gruijl
Journal:  Clin Exp Immunol       Date:  2020-05-06       Impact factor: 4.330

2.  Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Dariusz Łaski; Zbigniew Śledziński; Zbigniew Kmieć
Journal:  Sci Rep       Date:  2018-08-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.